Top Tweets for #FABTech
New to roll forming or want to sharpen your knowledge? Brian Rodgers presents Roll Forming Basics at #FABTECH 2026 Wed Oct 21, 11:00-11:45 AM. From simple machines to full integrated lines, Brian covers it all. https://t.co/f5tdlB3EPI
#RollForming #MetalForming #Manufacturing

@ultimatebanger1 ThanQ for you Kind Word.😍
#Trualt : Last 3 days Candle indicating accumulation before BO. Expecting BO abve 178 in 75M TF
#Fabtech : BO above 183 DCB
#FABTECH
Clean trendline breakout in progress.👀
✅ Structure improving
✅ Buyers stepping in
🎯 A sustained move above ₹165 could unlock the next leg up.
Smart money enters before the headlines.
Logic Behind Every Trade.
#SwingTrading #PriceAction #NIFTY #Stocks #NSE #BSE

📈 Added FABTECH Technologies to my portfolio today at ₹158.03.
Let's see how this story unfolds over the coming months. 🚀
⚠️ Not a buy/sell recommendation. Do your own research.
#FABTECH #PortfolioUpdate #ALPHX
Top 20 Swing Momentum Stocks
#ORBTEXP
#NIITLTD
#AARTECH
#FABTECH
#HEADSUP
#TCPLPACK
#PREMEXPLN
#ASTAR
#SINTERCOM
#SURANATP
#ATLANTAELE
#CHEMBONDCH
#NIITMTS
#LAXMICOT
#SHRADHA
#TATACONSUM
#BEEKAY
#MAGNUM
#INVPRECQ
#MEDANTA
Keep them on your watchlist for upcoming swing opportunities.
DM to join short term swing trading group.
#stockmarket #nifty
Fabtech Technologies Ltd having unique business model & presence in more than 62 countries.
#FABTECH
https://t.co/y36L5o4mmh
🍹POST RESULT REVIEW – FY26 – SME Stocks with potential to re-rate
2. FABTECH CLEANROOMS Rs.395 at 31p/e (Valuation has flared up. BUT ......)
Peer: HVAX Rs.623 at 12p/e
(HVAX was at Rs.813 on result day at 16p/e and has corrected after result. Good topline growth bur telative to H2Fy25 margin contracted from 14% to 10%)
NOTE FROM IPO REVIEW:
“Company manufactures cladding panels for walls & roofs of clean rooms. These are sandwiched panels with core as rockwool or polyurethane foam. It has 70,000sft factory in Valsad and 25,000sft factory (under subsidiary Altair Partition Systems LLP) at Murbad.
Out of Rs.27.74Cr IPO, Rs.14Cr for working capital and Rs.5.5Cr for investment in Kelvin Air Conditioning and Ventilation Systems Private Limited to raise its total holding to 51% from the present 33%"
Kelvin is into HVAC system design and fabrication and became 60% subsidiary in H2Fy26
OUTLOOK:
Company is taking up Clean Room Panel manufacturing with project execution (EPC) as well as HVAC system supply and execution after acquisition of KELVIN. This has increased the potential for growth and is reflected in much higher P/E compared to HVAX. Company has announced multiple Clean Room as well as HVAC orders, recently
If the company reports about 140Cr sales in H1FY27 (similar to recent H2), then TTM PAT can move upto 25Cr from 15.8Cr currently. This would give an EPS of Rs. 20. And at lower p/e of 25x (compared to 31x currently), stock should be at least Rs.500 by H1Fy27
So ideally, a good correction from the present Rs.395 towards Rs.250 -300 could give safety for new investors.
There is also possibility of valuation getting maintained at around 30x . That can give big returns since at TTM EPS of Rs.20, stock can move towards Rs.600 to 650.
So there is risk. There is opportunity too. Nothing can be certain anyway.
………………………………………………….
FY26 RESULTS for Quick Reference:
H2 FY26 Vs.H1 FY26
REV: Rs. 144Cr Rs. Vs Rs. 77Cr
PAT: Rs. 12.5Cr Vs Rs. 3.3Cr
(May Compare with H2FY25 Rev=Rs.89Cr & PAT=Rs. 8Cr )
FY26 Vs FY25
REV: Rs. 222Cr Vs Rs. 151Cr
PAT: Rs.15.8Cr Vs Rs. 13.3Cr
Fabtech Cleanrooms SME IPO was in Jan 2025 was at Rs.85 at 13x
..............................
🍹POST RESULT REVIEW – FY26 – SME Stocks with potential to re-rate
1. PARMESHWAR METAL Rs.191 at 9p/e Link: https://t.co/9ipM62SBVu
🚀📈 𝗦𝗧𝗥𝗢𝗡𝗚 𝗦𝗠𝗘 𝗖𝗢𝗠𝗣𝗔𝗡𝗜𝗘𝗦
𝗪𝗜𝗧𝗛 𝗦𝗨𝗣𝗘𝗥 𝗚𝗥𝗢𝗪𝗧𝗛 𝗚𝗨𝗜𝗗𝗔𝗡𝗖𝗘 🔥
Companies showing strong execution, visible growth & aggressive FY27 expansion plans 👀⚡
1️⃣ #NamoEWaste
2️⃣ #Aimtron
3️⃣ #AkikoGlobal
4️⃣ #Fabtech
5️⃣ #IndoSMC
6️⃣ #KRM
7️⃣ #Prizor
8️⃣ #VMarcIndia
9️⃣ #YashHighvoltage
🔟 #MaxvoltEnergy
1️⃣1️⃣ #AnonditaMedicare
1️⃣2️⃣ #GCH
1️⃣3️⃣ #Monolithisch
1️⃣4️⃣ #OBSCPerfection
1️⃣5️⃣ #HemantSurgical
1️⃣6️⃣ #Unihealth
1️⃣7️⃣ #AmiableLogistics
1️⃣8️⃣ #InfluxHealthtech
1️⃣9️⃣ #LTELE
📌 Key Themes Driving Growth 👇
✅ Strong Order Books
✅ Capacity Expansion
✅ Margin Improvement
✅ Sector Tailwinds
✅ Scalable Business Models
✅ Aggressive FY27 Guidance
⚠️ SME investing carries higher risk due to liquidity & volatility. Track valuations, execution & management quality carefully.
#SMEStocks #SmallCap #Microcap #StockMarket #IndianStockMarket #GrowthStocks #Investing #ResultSeason #TrendingStocks #BullRun 🚀

TILL NOW GOOD Q4 RESULT POSTED COMPANIES
#GRSE
#IIFL
#SKIPPER
#ANGELONE
#GROWW
#GREENPLY
#BAJAJCON
#PNBHOUSING
#CEAT
#FABTECH
#WAAREE RENEWABLE
#CEMPRO
#SGFIN
#ULTRATECH
#SUPREME
#RESULT
#STOCKMARKETINDIA
#NIFTY50
#CNXSMALLCAP
#FABTECH
Disc.: This is not a Buy, Sell or Hold recommendation. Please consult your Financial advisor before taking any investment decision.

#FABTECH
🚀 Fabtech Technologies – A Hidden Global EPC Player in Pharma Infra?
From ₹900Cr+ order book to strong global execution… this one deserves attention 👀
Let’s break it down 👇
⸻
1️⃣ What does Fabtech do?
Fabtech Technologies builds turnkey pharma, biotech & healthcare facilities 🌍
They handle everything:
⚙️ Process systems
🌬️ Cleanroom (Air)
💧 Water systems
➡️ One-stop solution = big competitive advantage
⸻
2️⃣ Why Turnkey Model is Powerful 🧠
Instead of multiple vendors, Fabtech offers:
✅ Single accountability
✅ Faster execution
✅ Better compliance (USFDA, EU-GMP, WHO)
➡️ Reduces delays + improves margins
⸻
3️⃣ Massive Order Book 📦
₹900+ Cr order book (Mar 2026)
➡️ Strong revenue visibility
➡️ Multi-year execution pipeline
➡️ Growth visibility already locked in
⸻
4️⃣ Global Business, Not India Story 🌍
78% revenue comes from:
🇦🇪 UAE
🇸🇦 Saudi Arabia
🌍 Africa & other regions
📈 Kenya revenue grew 236% YoY
➡️ Fabtech is riding global pharma infra demand
⸻
5️⃣ Financial Growth Snapshot 📊
FY26 numbers:
💰 Revenue: ₹431 Cr (+28%)
⚙️ EBITDA: ₹55.5 Cr (+18%)
💵 PAT: ₹38 Cr (+17%)
➡️ Consistent + healthy growth, not hype-driven
⸻
6️⃣ Balance Sheet Improvement 🔥
💵 Cash: ₹208 Cr (vs ₹35 Cr last year 😳)
📉 Debt reduced to ₹42 Cr
➡️ Huge improvement in financial strength
⸻
7️⃣ Execution Strength Matters 🛠️
Despite:
🚢 Logistics issues
📦 Freight cost spikes
🌍 Global disruptions
➡️ Fabtech delivered steady performance
That’s a BIG positive in EPC-type businesses
⸻
8️⃣ Strategic Expansion 🚀
Fabtech is entering high-growth areas:
💉 Vaccines
🐄 Animal Health
🏗️ Advanced pharma infra
📍 Projects in Saudi & Africa
➡️ Moving towards high-value segments
⸻
9️⃣ Key Project Wins 💼
✔️ West Africa OSD facility (~₹63 Cr)
✔️ Saudi vaccine project (~₹65 Cr)
✔️ North Africa EU-GMP facility
➡️ Strengthening global presence
⸻
🔟 Business Model Advantage 🧩
Fabtech runs an asset-light, integrated model
➡️ In-house manufacturing
➡️ Less dependency on vendors
➡️ Faster delivery
➡️ Better scalability
⸻
1️⃣1️⃣ Future Growth Drivers 📈
Growth will be driven by:
🔹 Strong order pipeline
🔹 Geographic expansion
🔹 Focus on complex projects
➡️ Long runway visible
⸻
1️⃣2️⃣ Risks ⚠️
• Global exposure (currency + geopolitics)
• Execution delays (EPC nature)
• Working capital cycles
➡️ Keep these in mind
⸻
1️⃣3️⃣ Final Take 🧠
Fabtech is not just another EPC company…
It’s building a global pharma infrastructure play 🌍
With:
✔️ Strong order book
✔️ Improving balance sheet
✔️ Global expansion
➡️ This could be an under-the-radar compounder 👀
⸻
#Fabtech #Stocks #Smallcap #Investing #StockMarketIndia #Multibagger #Pharma #EPC

#FABTECH
🚀 Fabtech Technologies – A Hidden Global EPC Player in Pharma Infra?
From ₹900Cr+ order book to strong global execution… this one deserves attention 👀
Let’s break it down 👇
⸻
1️⃣ What does Fabtech do?
Fabtech Technologies builds turnkey pharma, biotech & healthcare facilities 🌍
They handle everything:
⚙️ Process systems
🌬️ Cleanroom (Air)
💧 Water systems
➡️ One-stop solution = big competitive advantage
⸻
2️⃣ Why Turnkey Model is Powerful 🧠
Instead of multiple vendors, Fabtech offers:
✅ Single accountability
✅ Faster execution
✅ Better compliance (USFDA, EU-GMP, WHO)
➡️ Reduces delays + improves margins
⸻
3️⃣ Massive Order Book 📦
₹900+ Cr order book (Mar 2026)
➡️ Strong revenue visibility
➡️ Multi-year execution pipeline
➡️ Growth visibility already locked in
⸻
4️⃣ Global Business, Not India Story 🌍
78% revenue comes from:
🇦🇪 UAE
🇸🇦 Saudi Arabia
🌍 Africa & other regions
📈 Kenya revenue grew 236% YoY
➡️ Fabtech is riding global pharma infra demand
⸻
5️⃣ Financial Growth Snapshot 📊
FY26 numbers:
💰 Revenue: ₹431 Cr (+28%)
⚙️ EBITDA: ₹55.5 Cr (+18%)
💵 PAT: ₹38 Cr (+17%)
➡️ Consistent + healthy growth, not hype-driven
⸻
6️⃣ Balance Sheet Improvement 🔥
💵 Cash: ₹208 Cr (vs ₹35 Cr last year 😳)
📉 Debt reduced to ₹42 Cr
➡️ Huge improvement in financial strength
⸻
7️⃣ Execution Strength Matters 🛠️
Despite:
🚢 Logistics issues
📦 Freight cost spikes
🌍 Global disruptions
➡️ Fabtech delivered steady performance
That’s a BIG positive in EPC-type businesses
⸻
8️⃣ Strategic Expansion 🚀
Fabtech is entering high-growth areas:
💉 Vaccines
🐄 Animal Health
🏗️ Advanced pharma infra
📍 Projects in Saudi & Africa
➡️ Moving towards high-value segments
⸻
9️⃣ Key Project Wins 💼
✔️ West Africa OSD facility (~₹63 Cr)
✔️ Saudi vaccine project (~₹65 Cr)
✔️ North Africa EU-GMP facility
➡️ Strengthening global presence
⸻
🔟 Business Model Advantage 🧩
Fabtech runs an asset-light, integrated model
➡️ In-house manufacturing
➡️ Less dependency on vendors
➡️ Faster delivery
➡️ Better scalability
⸻
1️⃣1️⃣ Future Growth Drivers 📈
Growth will be driven by:
🔹 Strong order pipeline
🔹 Geographic expansion
🔹 Focus on complex projects
➡️ Long runway visible
⸻
1️⃣2️⃣ Risks ⚠️
• Global exposure (currency + geopolitics)
• Execution delays (EPC nature)
• Working capital cycles
➡️ Keep these in mind
⸻
1️⃣3️⃣ Final Take 🧠
Fabtech is not just another EPC company…
It’s building a global pharma infrastructure play 🌍
With:
✔️ Strong order book
✔️ Improving balance sheet
✔️ Global expansion
➡️ This could be an under-the-radar compounder 👀
⸻
#Fabtech #Stocks #Smallcap #Investing #StockMarketIndia #Multibagger #Pharma #EPC

#FABTECH Concall Takeaways
• 📈 ~25% Growth visibility ahead
• 💰 Margin expansion: 9.9% → 10.5%
• 📦 Order book growth: 25–30% YoY
• 🎯 FY27 Revenue target intact: ₹530–600 Cr
• 🔥 FY28 PAT guidance: 12–14% on track
Internal Targets:
• Contribution Margin ~45%
• EBITDA: 13–14%
• PAT: 9–11%
➡️ Strong execution + clear visibility = Bullish structure 📊
#StockMarket #SmallCap #Earnings #GrowthStocks
Fabtech Technologies Cleanrooms Ltd (SME) H2FY26 Results:-
#H2FY26 #Stockmarket #Nifty #Fabtech
Revenue 143.14 Cr vs 88.10 Cr (+62.47% YoY)
EBITDA 16.62 Cr vs 8.80 Cr (+89.02% YoY)
EBITDA Margin 11.61% vs 9.98% YoY
PBT Ex-Exceptional Items 15.35 Cr vs 8.84 Cr
(+73.56% YoY)
PAT 13.29 Cr vs 8.02 Cr (+65.71% YoY)
PAT After Minority interest 12.49 Cr vs 7.95 Cr (+57.03% YoY)
Other Income 1.38 Cr vs 0.56 Cr YoY

🔥Top 06 Best Setup Stocks for Today ( 29-04-2026 ) 📊
- 20-30% Upside Potential in Swing Basis for Next Week.
Save it for Later 🔖
1. #FABTECH - smc setup stock 💚
Above 174


Fabtech Technologies Q4 FY26: Management on Modular Lab Solutions and Revenue Growth #fabtechtechnologies #fabtech #pharmaengineering #q4fy26 #managementcommentary #turnkeyprojects
https://t.co/EYmqmFeWGD

Most Popular Users

Elon Musk 
@elonmusk
241M followers

Barack Obama 
@barackobama
119.2M followers

Cristiano Ronaldo 
@cristiano
111.9M followers

Donald J. Trump 
@realdonaldtrump
111.8M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
98M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
91.2M followers

KATY PERRY 
@katyperry
88.4M followers

Taylor Swift 
@taylorswift13
82.2M followers

Lady Gaga 
@ladygaga
73.8M followers

Virat Kohli 
@imvkohli
71M followers

Kim Kardashian 
@kimkardashian
70.1M followers

YouTube 
@youtube
68.7M followers

Bill Gates 
@billgates
64.3M followers

Neymar Jr 
@neymarjr
63.9M followers

The Ellen Show
@theellenshow
62.4M followers

CNN 
@cnn
61.8M followers

Selena Gomez 
@selenagomez
61.4M followers

X 
@x
60.8M followers






















